

## Appointment of Joint Company Secretary

Rhythm Biosciences Ltd (ASX: **RHY**) (“**Rhythm**” or the “**Company**”) advises that it has pointed Mr. James Barrie as Joint Company Secretary of RHY effective 1 January 2024. Mr. Barrie is a professional Company Secretary and Director, and the Board welcomes his assistance moving forward.

Ms. Andrea Steele will continue in her role as Joint Company Secretary and General Counsel of RHY and work with Mr. Barrie to ensure a smooth transition into the role.

For the purposes of ASX Listing Rule 12.6, Mr. Barrie will be the person responsible for communications with the ASX in relation to ASX Listing Rule matters.

- ENDS -

### Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com) or on +61 3 8256 2880:

<b>Mr. Otto Buttula</b> Executive Chairman	<b>Ms. Andrea Steele</b> General Counsel & Company Secretary
---	---

### About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

### About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience’s simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.